Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

Abstract

CPT-11 has significant activity in refractory cervical carcinoma. Gastrointestinal intolerance and hematologic toxicity must be monitored carefully. Further studies of alternative schedules may improve the tolerance and response rate.